Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111-In-DOTA-cG250
- Development stage
- Unknown
- Lead developer
- Radboud University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111-In-DOTA-cG250 is a radiolabeled chimeric monoclonal antibody targeting carbonic anhydrase IX (CAIX), also known as G250, which is highly expressed in renal cell carcinoma and some other tumors. The antibody cG250 is conjugated to the chelator DOTA and labeled with the radioisotope indium-111, enabling its use as a diagnostic radiopharmaceutical for imaging via single-photon emission computed tomography (SPECT). By binding specifically to CAIX-expressing tumor cells, it allows for non-invasive localization and assessment of tumors using gamma scintigraphy. Its primary development has been in the context of neoplasms, particularly metastatic renal cell carcinoma[1][4][5].
- Other names
- Indium In 111-DOTA-girentuximab[111In]-DOTA-cG250
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 111-In-DOTA-cG250.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111-In-DOTA-cG250.